Thomas R. Staab II
2019
In 2019, Thomas R. Staab II earned a total compensation of $910.4K as Senior Vice President and Chief Financial Officer at BioCryst Pharmaceuticals, a 49% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $157,311 |
|---|---|
| Option Awards | $276,365 |
| Salary | $462,679 |
| Other | $14,000 |
| Total | $910,354 |
Staab received $462.7K in salary, accounting for 51% of the total pay in 2019.
Staab also received $157.3K in non-equity incentive plan, $276.4K in option awards and $14K in other compensation.
Rankings
In 2019, Thomas R. Staab II's compensation ranked 9,706th out of 13,971 executives tracked by ExecPay. In other words, Staab earned more than 30.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,706 out of 13,971 | 31st |
Division Manufacturing | 3,913 out of 5,701 | 31st |
Major group Chemicals And Allied Products | 1,493 out of 2,200 | 32nd |
Industry group Drugs | 1,277 out of 1,886 | 32nd |
Industry Biological Products, Except Diagnostic Substances | 286 out of 389 | 27th |
Source: SEC filing on March 31, 2020.
Staab's colleagues
We found four more compensation records of executives who worked with Thomas R. Staab II at BioCryst Pharmaceuticals in 2019.
2019
Jon Stonehouse
BioCryst Pharmaceuticals
Chief Executive Officer
2019
Megan Sniecinski
BioCryst Pharmaceuticals
Senior Vice President and Chief Business Officer
2019
Yarlagadda Babu
BioCryst Pharmaceuticals
Senior Vice President of Drug Discovery
2019
William Sheridan
BioCryst Pharmaceuticals